Webinar Recorded on December 5, 2025                                     Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Dry Eye Disease (DED) is a common multifactorial inflammatory condition characterized by loss of tear film homeostasis. DED can lead to a plethora of signs and symptoms that cause patients discomfort and visual disturbance including dryness, visual fatigue, blurry vision, redness, photophobia, burning and itching, and foreign body sensation. DED has a negative impact on many aspects of people's lives, including functional vision and overall health status. DED has been found to affect patients' daily activities, lead to pain or discomfort, and impact their work productivity.

The prevalence of DED globally has been estimated to affect approximately 9%, with some reports of prevalence as high as 50% meaning millions of people are experiencing DED. In the US, the estimated prevalence is between 5.3% and 6.8% of adults.

DED is perpetuated by a continual cycle of tear film instability, tear hyperosmolarity, apoptosis, and inflammation. This self-sustaining cycle can lead to the chronic form of DED. Inflammation is a key driver of this DED cycle and some of the mechanisms of the inflammatory cascade will be discussed.

We are pleased to have Dr. Laura Periman, MD, Founder and Director of Dry Eye Services and Clinical Research at Periman Eye Institute, Seattle, WA, provide our online seminar. She is an internationally recognized expert in dry eye disease with extensive clinical and research experience. She will provide her impactful expertise in the understanding of the DED cycle, treatment options and some of the challenges patients face when trying to access new therapies.

References

1. Craig JP, et al. Ocul Surf. 2017;15(3):276-283.
2. Bu J, et al. Antioxidants (Basel). 2024;13(4):422.
3. Bartlett JD, et al. Clin Ophthalmol. 2015;9:1719-1730.
4. Boboridis KG, et al. BMJ Open. 2023;13(3):e067007.
5. Morthen MK, et al. Ocul Surf. 2021;21:107-117.
6. Papas EB. Ophthalmic Physiol Opt. 2021;41:1254-1266.
7. Stapleton F, et al. Ocul Surf. 2017;15(3);334-365.
8. Farrand KF, et al. Am J Ophthalmol. 2017;182:90-98.
9. Dana R, et al. Am J Ophthalmol. 2019;202:47-54.
10. Gupta PK, et al. Eye Contact Lens. 2020;46(suppl 2):S64-S69.
11. Bron AJ, et al. Ocul Surf. 2017;15(3):438-510.
12. Pflugfelder SC, et al. Ophthalmology. 2017;124(11S):S4-S13.
13. Periman LM, et al. J Ocul Pharmacol Ther. 2020;36(3):137-146.
14. Yu L, et al. Front Pharmacol. 2021;12:732887.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.